NSE ScannerChemicals · Chemicals: Specialty · NSE: FISCHER · data 2026-10-31
Fischer Medical Ventures Ltd
In plain words
Price: 79.2% below its 52-week high of ₹119.4.
Delivery: 44.7% of traded shares were kept for delivery over the last 10 sessions, against 55.1% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹367 cr |
| Net profit (last 12 months) | ₹30 cr |
| Sales growth, 3 years (yearly) | 1097.9% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 63.1% (+1.3 pts in a year), pledged 6.8%, institutions 8.0%.
P/E 55.6, dividend yield 0.2%. Price relative to earnings and book value (low is cheaper, not better).
ROE 8.9%, ROCE 12.8%, operating margin 12.7%: how much profit it earns on the money it uses.
Debt/equity 0.28, Profit growth — and sales growth 1097.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Promoters raised their holding by 1.3 points in a year.
- Promoters have pledged 6.8% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
32/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 39.6% over the last 20 sessions vs 59.8% in the 40 before (0.66x); shares delivered per day 0.92x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 11/20: Net +₹1.01 cr bought in bulk/block deals over 90 days (0.25x a usual day's traded value); 1 net buying day, 0 net selling days.
- Insider / SAST buys 12/15: 0 insider buy days (promoter group among them) and 3 SAST acquisition days in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Deal ● Insider ● Split
- 22 Sept 26Dividend Dividend ₹0.05 (ex-date) +6.6% next session
- 22 Sept 26Deal Bulk deal: TRADE SOLVENT PRIVATE LIMITED bought ₹21.21 cr (net +₹1.01 cr) +6.6% next session
- 21 Aug 26Insider SAST disclosure: FMV Holdings Pte Ltd acquired 4,54,210 shares -6.4% next session
- 18 Aug 26Insider SAST disclosure: FMV Holdings pte Ltd +5 acquired 3,12,45,790 shares +4.5% next session
- 17 Aug 26Insider SAST disclosure: Shankar Varadharajan acquired 23,00,000 shares -1.3% next session
- 22 Sept 25Dividend Dividend ₹0.01 (ex-date) +1.2% next session
- 12 Sept 25Split Split: face value ₹10 → ₹1 (ex-date) -1.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 63.08% | 62.15% | 62.15% | 61.80% |
| Foreign institutions (FII) | 6.71% | 5.48% | 4.97% | 4.85% |
| Domestic institutions (DII) | 1.26% | 1.35% | 1.38% | 1.36% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 5.01% | 5.04% | 4.53% | 3.88% |
| Number of shareholders | 25,676 | 23,950 | 23,269 | 22,920 |
Common questions
How much do promoters hold in Fischer Medical Ventures Ltd?
Promoters held 63.08% of Fischer Medical Ventures Ltd at the end of Sept 2026, with 6.81% of promoter shares pledged.
Is Fischer Medical Ventures Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.28.
What is Fischer Medical Ventures Ltd's P/E ratio?
About 55.6, based on the last 12 months' earnings and a price of ₹24.79 (data 2026-10-31).
What is the 52-week high and low of Fischer Medical Ventures Ltd?
The 52-week high is ₹119.4 and the 52-week low is ₹21.78.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Fischer Medical Ventures Ltd | ₹24.79 | ₹1,620 cr | 55.6 | — | 8.9% | 12.8% | 0.28 | -78.8% |
| S H Kelkar and Company Ltd | ₹125.34 | ₹1,740 cr | 19.5 | — | 5.3% | 8.5% | 0.76 | -44.9% |
| IG Petrochemicals Ltd. | ₹531.1 | ₹1,636 cr | 20 | — | 0.2% | 4.4% | 0.27 | +27.4% |
| Camlin Fine Sciences Limited | ₹84.1 | ₹1,615 cr | 392.4 | — | -2.8% | 2.3% | 0.69 | -58.5% |
| Bhageria Industries Ltd. | ₹362.45 | ₹1,581 cr | 14 | 2.3 | 8% | 8% | 0.19 | +68.4% |
| Thirumalai Chemicals Limited | ₹114.33 | ₹1,374 cr | — | — | -12.3% | -3.5% | 1.39 | -59.4% |
Compare FISCHER with SHK in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open FISCHER in NSE Scanner →